Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials

European Journal of Cancer

Volumn 40, Issue 4, 2004, Pages 474-480

  Moser, E C ^a,b   Noordijk, E M ^b   Van Glabbeke, M ^a   Teodorovic, I ^a   De Wolf Peeters, C ^c   Carde, P ^d   Baars, J W ^e   Tirelli, U ^f   Raemaekers, J M M ^g   Kluin Nelemans, J C ^h  

^a EORTC DATA CENTER   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Antoni van Leeuwenhoekziekenhuis ^*  (Netherlands)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advanced aggressive NHL; CHVmP BV regimen; Long term outcome; Sub set analyses

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DATA ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; HISTOLOGY; HUMAN; LONG TERM CARE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE;

EID: 10744220685     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.003     Document Type: Article

References (15)

1. Raemaekers J.M., Kluin-Nelemans J.C., Teodorovic I.et al. The achievements of the EORTC Lymphoma Group. Eur J Cancer. 38(Suppl. 4):2002;S107-S113.
2. Carde P., Meerwaldt J.H., van Glabbeke M.et al. Superiority of second over first generation chemotherapy in a randomised trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group. Ann Oncol. 2:1991;431-435.
3. Somers R., Carde P., Thomas J.et al. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol. 5(Suppl. 2):1994;85-89.
4. Meerwaldt J.H., Carde P., Somers R.et al. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm- 26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. Ann Oncol. 8(Suppl. 1):1997;67-70.
5. Kluin-Nelemans J.C., Zagonel V., Anastasopoulou A.et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomised phase III EORTC study. J Natl Cancer Inst. 93:2001;22-30.
6. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer. 49:1982;2112-2135.
7. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 329:1993;987-994.
8. WHO Handbook for Reporting Results of Cancer Treatment. 1997;WHO, Geneva, Switzerland.
9. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457.
10. Breslow N. Comparison of survival curves. Buyse M.E. Cancer Clinical Trials Methods and Practice. 1988;382-406 Oxford Medical Publications, Oxford, UK.
11. Cox D.R. Regression models and life-table. J R Stat Soc. 34:1972;187-220.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
13. Fisher R.I., Gaynor E.R., Dahlberg S.et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 328:1993;1002-1006.
14. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 89:1997;3909-3918.
15. Teodorovic I., Pittaluga S., Kluin-Nelemans J.C.et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organisation for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 13:1995;2819-2826.